X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MERCK LTD - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA MERCK LTD GSK PHARMA/
MERCK LTD
 
P/E (TTM) x 61.7 45.4 135.8% View Chart
P/BV x 11.5 6.6 174.1% View Chart
Dividend Yield % 2.5 0.5 487.4%  

Financials

 GSK PHARMA   MERCK LTD
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
MERCK LTD
Dec-17
GSK PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2,7601,358 203.3%   
Low Rs2,040933 218.6%   
Sales per share (Unadj.) Rs339.0665.0 51.0%  
Earnings per share (Unadj.) Rs41.456.6 73.2%  
Cash flow per share (Unadj.) Rs45.972.5 63.3%  
Dividends per share (Unadj.) Rs35.0015.00 233.3%  
Dividend yield (eoy) %1.51.3 111.3%  
Book value per share (Unadj.) Rs242.9441.7 55.0%  
Shares outstanding (eoy) m84.7016.60 510.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.11.7 411.1%   
Avg P/E ratio x57.920.2 286.2%  
P/CF ratio (eoy) x52.315.8 330.9%  
Price / Book Value ratio x9.92.6 381.1%  
Dividend payout %84.526.5 318.7%   
Avg Mkt Cap Rs m203,28019,011 1,069.3%   
No. of employees `000NA1.5 0.0%   
Total wages/salary Rs m5,2341,696 308.5%   
Avg. sales/employee Rs ThNM7,150.0-  
Avg. wages/employee Rs ThNM1,098.7-  
Avg. net profit/employee Rs ThNM608.2-  
INCOME DATA
Net Sales Rs m28,71511,040 260.1%  
Other income Rs m545240 227.5%   
Total revenues Rs m29,26011,279 259.4%   
Gross profit Rs m5,0591,376 367.6%  
Depreciation Rs m380264 143.9%   
Interest Rs m20-   
Profit before tax Rs m5,2221,352 386.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m178170 104.7%   
Tax Rs m1,892583 324.6%   
Profit after tax Rs m3,508939 373.5%  
Gross profit margin %17.612.5 141.3%  
Effective tax rate %36.243.1 84.0%   
Net profit margin %12.28.5 143.6%  
BALANCE SHEET DATA
Current assets Rs m21,8157,523 290.0%   
Current liabilities Rs m15,9992,253 710.2%   
Net working cap to sales %20.347.7 42.4%  
Current ratio x1.43.3 40.8%  
Inventory Days Days6452 121.9%  
Debtors Days Days1941 46.1%  
Net fixed assets Rs m12,4751,240 1,006.3%   
Share capital Rs m847166 510.2%   
"Free" reserves Rs m19,7267,167 275.3%   
Net worth Rs m20,5737,333 280.6%   
Long term debt Rs m60-   
Total assets Rs m39,4759,912 398.2%  
Interest coverage x2,612.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.1 65.3%   
Return on assets %8.99.5 93.9%  
Return on equity %17.112.8 133.1%  
Return on capital %26.220.8 126.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5641,015 55.6%   
Fx outflow Rs m7,4293,043 244.2%   
Net fx Rs m-6,865-2,028 338.5%   
CASH FLOW
From Operations Rs m4,728537 881.1%  
From Investments Rs m-1,042-476 218.7%  
From Financial Activity Rs m-3,066-220 1,395.1%  
Net Cashflow Rs m620-160 -388.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 51.8 97.9%  
Indian inst/Mut Fund % 10.2 18.2 56.0%  
FIIs % 23.8 1.0 2,380.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 29.1 52.9%  
Shareholders   102,036 28,591 356.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   ORCHID PHARMA LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  SUVEN LIFE  IPCA LABS  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red, Global Markets Cautious, and Top Stocks in Action(Pre-Open)

On Monday, share markets in India opened on a positive note and ended the day in red after a volatile day of trading.

Related Views on News

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Nov 12, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS